Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma

Chinese Journal of Cancer

Volumn 31, Issue 4, 2012, Pages 197-206

  Li, Guo ^a   Gao, Jin ^a   Tao, Ya La ^a   Xu, Bing Qing ^a   Tu, Zi Wei ^a   Liu, Zhi Gang ^a   Zeng, Mu Sheng ^a   Xia, Yun Fei ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ALP; GGT; LDH; Nasopharyngeal carcinoma; Prognosis

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER CENTER; CANCER PATIENT; CANCER PROGNOSIS; CHINA; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ALKALINE PHOSPHATASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CISPLATIN; FEMALE; FLUOROURACIL; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE; YOUNG ADULT;

EID: 84860171928     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10283     Document Type: Article

References (38)

1. Li ZQ, Xia YF, Liu Q, et al. Radiotherapy-re lated typing in 842 patients in canton with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 2006,66:1011-1016.
2. Cho WC. Most common cancers in Asia-Pacific region: nasopharyngeal carcinoma. In: Cancer report of Asian-Pacific region 2010. Asian Pacific Organization for Cancer Prevention, 2010:284-289.
3. Leung TW, Tung SY, Sze WK, et al. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck, 2005,27:555-565.
4. Xia YF, Qian JY, Zhang EP. Practical radiotherapy of nasopharyngeal carcinoma. Beijing: Peking University Medical Publishing House, 2003.
5. Cascante M, Centelles JJ, Veech RL, et al. Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation. Nutr Cancer, 2000,36:150-154.
6. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006,9:425-434.
7. Wei JS, Chung NC, Wei LL, et al. High-m olecular-mass alkaline phosphatase as a tumor marker for colorectal cancer: comparison of two test methods. Clin Chem, 1993,39:540-543.
8. Stinghen ST, Moura JF, Zancanella P, et al. Specific immunoassays for placental alkaline phosphatase as a tumor marker. J Biomed Biotechnol, 2006,2006:56087.
9. Corti A, Franzini M, Paolicchi A, et al. Gamma- glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res, 2010,30:1169-1181.
10. Lu XG, Zhu YQ, Feng Y, et al. The relationship between serum LDH and distant metastasis of nasopharyngeal carcinoma. Acta Academiae Medicinae Suzhou, 2000,20:243-253. [in Chinese]
11. Cheng SH, Jian JJ, Tsai SY, et al. Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys, 1998,41:755-762.
12. Cheng SH, Tsai SY, Horng CF, et al. A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy. Int J Radiat Oncol Biol Phys, 2006,66:992-1003.
13. Stroeve EA, Makarova VG. Laboratory Manual in Biochemistry. Moscow: MIR Publishers, 1989.
14. Bidart JM, Thuillier F, Augereau C, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem, 1999,45:1695-1707.
15. Nicolaides C, Fountzilas G, Zoumbos N, et al. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-H odgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology, 1998,55:405-415.
16. Patel PS, Rawal GN, Balar DB. Combined use of serum enzyme levels as tumor markers in cervical carcinoma patients. Tumour Biol, 1994,15:45-51.
17. Warburg O. On the origin of cancer cells. Science, 1956,123: 309-314.
18. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-ce ll lung cancer tissues is linked to tumor hypoxia, angiogenic factor production and poor prognosis. Br J Cancer, 2003,89: 877-885.
19. Stokkel MP, van Eck-Smit BL, Zwiderman AH, et al. Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma. J Cancer Res Clin Oncol, 1998,124:215-219.
20. Zhao YH, Zhou M, Liu H, et al. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene, 2009,28:3689-3701.
21. Koukourakis MI, Giatromanolaki A, Simopoulos C, et al. Lactate dehydrogenase 5 (LDH5) relates to up-re gulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis, 2005,22:25-30.
22. Giatromanolaki A, Sivridis E, Gatter KC, et al. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2 (KDR) pathway and prognosis. Gynecol Oncol, 2006,103:912-918.
23. Kolev Y, Uetake H, Takagi Y, et al. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-in ducible factor (HIF-1a lpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol, 2008,15:2336-2344.
24. Arkenau HT, Barriuso J, Olmos D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol, 2009,27:2692-2696.
25. Fussenich LM, Desar IM, Peters ME, et al. A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer, 2011,47:1152-1160.
26. Xie H, Valera VA, Merino MJ, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther, 2009,8:626-635.
27. Stubbs M, McSheehy PM, Griffiths JR, et al. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today, 2000,6:15-19.
28. Colgan SM, Mukherjee S, Major P. Hypoxia-in duced lactate dehydrogenase expression and tumor angiogenesis. Clin Colorectal Cancer, 2007,6:442-446.
29. Harris AL. Hypoxia: a key regulatory factor in tumor growth. Nat Rev Cancer, 2002,2:38-47.
30. Rofstad EK. Microenvironment-in duced cancer metastasis. Int J Radiat Biol, 2000,76:589-605.
31. Maxwell PH. The HIF pathway in cancer. Semin Cell Dev Biol, 2005,16:523-530.
32. Harris, H. The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta, 1990,186:133-150.
33. Kojima Y, Sakurada T. Increase in alkaline phosphatase activity in the liver of mice bearing Ehrlich ascites tumor. Cancer Res, 1976,36:23-27.
34. Nilsson EE, Westfall SD, McDonald C, et al. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics. Cancer Chemother Pharmacol, 2002,49:93-100.
35. Rassam MB, Al-Bashir NN, Al-Salihi AR, et al. Heat-stable alkaline phosphatase. A putative tumor marker of head and neck squamous cell carcinoma. Acta Oncol, 1995,34:49-52.
36. Bao R, Selvakumaran M, Hamilton TC. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts. Gynecol Oncol, 2000,78:373-379.
37. Beltran-Martinez RJ, Correa-Chacon AJ. Diagnostic value of gamma-glutamyltransferase in the metastatic disease of patients with renal cell carcinoma. Gac Med Mex, 2003,139: 123-125.
38. Fentiman IS, Allen DS. Gamma-glutamyl transferase and breast cancer risk. Br J Cancer, 2010,103:90-93.